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EDITORIAL REVIEW
Is immunologic tolerance of self modulated through antigen
presentation by parenchymal epithelium?
A remarkable biology has emerged over the last 30 years
regarding T lymphocytes and their role in host defense against
infection and oncogenesis, in the rejection of foreign tissues
following transplantation, and in the spontaneous recognition of
self leading to autoimmune inflammation. With this biology has
come more knowledge regarding T lymphocyte function, the
role of helper, suppressor, and cytotoxic/delayed-type hyper-
sensitivity subsets, the molecular definition of T cell receptors
(TcR), their idiotypes and regulatory networks, and more
recently the biochemical processes of T cell signaling and
activation following antigen-presentation.
T cells, unlike antibodies, are not easily engaged by antigen.
Normally, a relevant antigen is presented to T lymphocytes
only after it has been internally processed by specialized
antigen-presenting cells within the lymphoid system. The target
ligand is first reduced to small peptide epitopes that eventually
link with fully assembled major histocompatibility complex
(MHC) molecules emerging from the golgi [1, 2]. MHC contain-
ing peptide is then transported for exhibition on the cell surface.
Most T cells recognizing self peptides are eliminated from the
repertoire during early thymic development by positive or
negative selection [3, 4]; when developing T cells contact
processed antigen in the thymus in the context of MHC, many
undergo apoptosis [5]. Only a chosen few are preserved for use
in the periphery [4]. This central mechanism of tolerance
reduces the total burden of autoreactive lymphocytes generated
following random recombinatorial diversity of TcRs during
ontogeny. Any residual self-reactive cells that escape the thy-
mus probably either had low affinity TcRs for self antigen [6], or
never encountered antigen because of its expression in an
extrathymic or privileged site [7]. Renegade T cells in disease-
free individuals are normally held at bay by mechanisms of
peripheral tolerance. These peripheral mechanisms include the
attenuation of cell-surface TcR [8], the reduced visibility of
MHC determinants on antigen-presenting cells [9—12], the
down-regulation of co-stimulatory molecules [13], immune sup-
pression [14, 15], and clonal anergy [16, 17]. While all five of
these peripheral mechanisms are well-described phenomena, in
the current molecular era, the latter three suffer in comparison
from the difficulty of not having clear event markers, nor a firm
structural basis in established biochemical process.
The most intuitively understood mechanisms of peripheral
tolerance are those which lower the levels of TcR on autoim-
mune T lymphocytes, those processes which deprive T cells of
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MHC molecules for presentation, and/or those which attenuate
associative-recognition molecules like CD4 or CD8. In my view
the most pivotal element in the maintenance of peripheral
tolerance is the interaction between TcR and its MHC-restric-
tion determinant. T lymphocytes are deaf and dumb without
visible expression of MHC restriction elements on antigen-
presenting cells [1, 18]; they can neither be activated, sup-
pressed, nor anergized. If CD4 helper T cells were totally
prevented from seeing class II in the periphery all the time,
there could be no recognition of self and no autoimmunity. This
is impractical for a normal host because these T cells would also
be unable to assist in the proper defense against infection or
surreptitious malignancies.
Activation of a TcR by a professional antigen-presenting cell
requires that antigenic peptides be expressed in the context of
MHC class II for CD4 helper cells or MHC class I for CD8
cytotoxic cells [19]. Macrophages, dendritic cells, and B lym-
phocytes serve this purpose. CD4 helper T cells also need
additional co-stimulatory signals from the antigen-presenting
cell to become fully activated [13]. Molecular interactions
between cells occur in stages involving a variety of determinant
interactions; CD4/MHC class II, LFA-1/ICAM1, and CTLA-4/
CD28/B7 represent a few of the several necessary associative-
recognition molecules [13, 19]. No one co .stimulator seems
absolutely pre-eminent, although the fans of CD28/B7 are
lobbying hard for beatification [13, 20].
When sell-reactive CD4 helper T cells are activated in
peripheral sites, subsequent autoantibodies or cell-mediated
immunity may lead to autoimmune inflammation. From classi-
cal teaching, the true immunologic periphery was only thought
to constitute satellite lymphoid tissue abundant in professional
antigen-presenting cells. It was eventually realized, however,
that macrophages and dendritic cells were also scattered
throughout parenchymal organs, like thyroid, liver, and kidney
[9, 10, 211 and that, perhaps, autoimmune responses could be
established locally at the site of emerging inflammation. In the
late 1970s into the mid-SOs a number of compelling experiments
demonstrated that non-lymphoid somatic cells were also capa-
ble of aberrantly increasing the numbers of MHC class II
molecules on their cell surface [reviewed in 9, 10], probably
following cytokine exposure in their local microenvironment
[11, 12]. These observations quickly lead to the hypothesis that
parenchymal cells, like epithelium, might also be able to pro-
cess and present antigenic peptides to autoimmune T lympho-
cytes [10, 22].
Evidence in support of this notion has been largely mounted
in vitro. Many laboratories using a variety of tissues have
demonstrated that epithelium from skin, kidney, retina, bron-
chi, and thyroid can present self [22—26] or non-self [23, 27—30]
antigens to preformed immune T cell clones or hybridomas.
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And while these studies used T cells of established specificity
rather than naive or uncommitted lymphocytes [31], most of
this work, nevertheless, made the general concept seem pretty
tidy from a theoretical perspective: in effect, T cells recognizing
self antigens that escape normal thymic elimination circulate in
and the under the control of peripheral tolerance. Something
happens to that tolerogenic process in an organ tissue like the
kidney. The vascular barrier to T cell migration is lifted, and
tissue penetration becomes possible. Concomitantly, MHC
class II determinants, which are normally not expressed by
epithelium, start appearing in increased number. Contact
through antigen is made with circulating CD4 helper T lym-
phocytes, autoimmunity engages, and more T cells accumulate
as the early vestiges of an inflammatory event [10]. Such a
senario, of course, would have to have some limits that serve
the self-protective interests of complex organisms. Perhaps
natural constraints, like evolutionary pressure, have made it
incrementally more difficult to get epithelial cells in organ
tissues to present antigens as efficiently as B lymphocytes,
macrophages, or dendntic cells [32]. Organ epithelium can
present self-proteins, as will be discussed below, but certain
conditions must be met.
In the current issue of Kidney International, Singer et al [33]
provide an interesting new wrinkle in this story by reporting
that tubular epithelium presenting antigens, under some condi-
tions, may induce non-responsiveness in T cells drawn into
cell-surface contact. The induction of what has now been
termed T cell anergy would be expected to attenuate autoim-
munity, not initiate or accelerate it. The Singer experiments are
borne out of previous in vitro observations that, if CD4 T cells
recognize antigen plus MHC class II without appropriate co-
stimulation, the result will be a lack of antigen-specific prolif-
eration [13, 16, 17]. These anergized cells are functionally inert
and make little IL-2 when rechallenged with antigen, but will
divide in response to the application of exogenous IL-2, or
allogeneic stimulation. Anergy can be distinguished from im-
munologic suppression by the fact that anergy cannot be
adoptively transferred to naive lymphocytes, while suppression
can [14]. Both anergy and suppression share one similar prob-
lem, however, while such phenomena can be convincingly
demonstrated in various ways, there is no general agreement on
single phenotypic event marks. The unfolding of the biochem-
ical and molecular programs for both will be of great interest to
many of us.
Anergy or suppression may partially explain why class II
MHC molecules are occasionally expressed in renal epithelium
in the absence of progressive inflammation. If T cell anergy is
going to emerge as an expected protective mechanism of
peripheral tolerance against autoimmunity, however, then more
in vivo experiments will be needed to show its application
towards true structural antigens that reflect normal parenchy-
mal-self. To date, only limited experiments using MIs superan-
tigens [34], or transgenic mice overexpressing class II Ea//3 in
pancreatic islets [35, 36] have been advanced to show anergy as
an in vivo mediator of peripheral tolerance. Two important,
recent transgenic experiments studying the expression of viral
proteins in the pancreas [37, 38], and a novel bone marrow
chimera experiment [31], further suggest that anergy may have
a few more hurdles to overcome in vivo. In both of the
transgenic experiments the mice developed normally, and did
not spontaneously express immune-mediated pancreatitis/dia-
betes until they were exposed to wild-type virus. The Ohashi
study [37] was far more revealing in mechanism because they
bred one set of transgenic mice expressing pancreatic viral
protein with other mice carrying a transgene for a T cell
receptor specific for a relevant viral epitope. Their comprehen-
sive report of various tests suggests that peripheral tolerance
before exposure to wild-type virus could not be explained by
clonal deletion, anergy, a reduction of T cell receptors, or a lack
of accessory molecules. None of these transgenic experiments,
however, convincingly eliminated suppression as an explana-
tion for the observed peripheral tolerance.
Suppression can be tested for in vivo, as in the case of
spontaneous interstitial nephritis [39], by the adoptive transfer
of regulatory lymphoid cells into an active autoimmune envi-
ronment. One expectation of effect would be the attenuation of
that autoimmune process. Suppression can also be examined in
vitro by culture, or short-term adoptive transfer of admixed
cells [401. Many recent tests for suppression (and anergy) have
used proliferation of T cells to antigen as an outcome measure-
ment. I have never understood this. T cell proliferation assays
are widely used in tolerance experiments because they are easy
and quantitative, but to be sure, they are functionless accounts
of immune recognition; that is to say, the subset function and
cytokine release of the T cells is not reflected by thymidine
incorporation. I am not aware any credible evidence that
organs, including the kidney, can be injured by the i.ntoward
effects of an antigen proliferation assay. Other kinds of func-
tional measures need to be made when testing for antigen-
specific effect [41]. CD4 helper T cells, for example, facilitate
either the development of antibody from B lymphocytes, or T
cell-mediated immunity by inducing cells capable of cytotoxic-
ity or delayed-type hypersensitivity. Future evidence for or
against anergy must grapple with this issue.
The further evaluation of T cell anergy in vitro will also need
to consider several experimental issues that all mechanisms of
tolerance must wrestle with if they are going to emerge as
something more than just a curiosity. For example, co-culture
experiments with T cells and epithelium reported recently [42,
43], including the Singer study [33], have only used single
clones to demonstrate the effect. If T cell anergy following
contact with antigen-presenting epithelium is going to play a
major role in peripheral tolerance, it has got to work most of the
time in most antigen-reactive T cells. Such a clonal analysis has
not been performed by anyone. Anergy may also only apply to
selected protein epitopes. Some epitopes may be activating and
others the opposite [44, 45]; the net effect in vivo might depend
on which set of epitopes were preferred or had more affinity for
MHC class II molecules [6]. Further studies will also need to
use peptide/antigen systems that are more reflective of disease-
associated, biosynthetic self-proteins. Applying exogenous anti-
gens to antigen-presenting epitheliuni to study T cell responses
raises a cosmetic question of applicability to autoimmunity, al-
though the processing of exogenously applied proteins or peptides
may not be all that different from the manner in which cells
process many forms of self [2].
The role of anergy as a mechanism of peripheral tolerance
was advanced when investigators started working with T cell
clones restimulated in culture rather than T cell hybridomas.
Hybridomas have been suggested to require less co-stimulation
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than T cell clones [reviewed in 461, and the experiments
demonstrating the antigen-presenting capacity of tubular [23,
27] and glomerular epithelium [28] to hybridomas, in retrospect,
might not have been expected to ever demonstrate anergy. Of
course, there are experiments using antigen-specific T cell
clones which demonstrate the opposite, that is, a proliferative
activation following exposure to epithelium [25, 30], including
tubular epithelium [22, 24]. In the latter case this activation was
CD4- and MHC-dependent. How these observations reconcile
with the recent reports of Singer and others is work for the
future. I suspect these two seemingly disparate set of observa-
tions represent two spectrums of possible biological effect.
The differences between stimulation and anergy may lie in the
phenotypic state of the T cell clones themselves, or in the
co-stimulatory capacity of the antigen-presenting cells captured
in culture. Most T cells started in culture emerge as CD4 Thl
cell lines, unless special care is given to the selective generation
of Th2 or CD8 lymphocytes. Th 1 cells usually express IL-2
and yIFN. 7IFN released during T cell contact would certainly
be expected to increase the levels of MHC class II determinants
[11, 12] as well as co-stimulatory molecules, like ICAM- 1, in
cultured tubular cells [46]. Whether the CD28/B7 system is
modulated in tubular cells by 7IFN is not yet known. Tubular
antigen-specific CD4 T cell clones reactive to tubular cells
carried in culture do not normally recognize tubular cells in vivo
following adoptive transfer, nor do they produce interstitial
inflammation [11]. The same cells, however, after the recipient
mouse is pretreated with yIFN, rapidly instigate nephritis. This
suggests that full activation of all co-stimulators in epithelium
will not lead to anergy.
Recent transgenic mouse experiments where cytokines, like
7IFN [47] and IL-2 [48], have been targeted for overexpression
in organ issues like the pancreas support the notion that local
activation signals are required for antigen-presentation by pa-
renchymal cells leading to autoimmune recognition and subver-
sion of tolerance. Likewise, for anergy to pertain in vivo, the
difficult circumstance of having MHC molecules expressed for
T cell contact must occur simultaneously with the non-expres-
sion of co-stimulatory molecules. How this suboptimal state for
T cell activation would appear and be maintained is not clear.
MHC class II determinants, for example, would have to be
differentially expressed relative to other co-stimulators. This
latter phenotype presumably reflects the kind of tubular cells
Singer and colleagues grew in culture for their experiments.
Since these epithelia were pretreated with 7IFN, one would
have anticipated their ability to fully activate T cells. Perhaps
the failure of the Singer cells to do so is related to the
mitomycin-pretreatment which may be analogous to too much
irradiation [49]. Additional experiments will be needed to sort
this out.
Where does this all leave us? The Singer experiments sug-
gest, as in earlier work in other systems [3, 17, 20, 36], that the
induction of T cell anergy by kidney epithelium must be
considered a potential mechanism of peripheral immunologic
tolerance. Of course, if anergy is preferred and biologically
protective following random T cell contact with parenchymal
cells, one must wonder how we ever get autoimmune disease or
allograft rejection. I happen to believe that autoimmune T cell
injury in organ tissues like the kidney is typically focused
towards epithelium or other differentiated somatic cells. CD4
helper T cells and their induction of CD8 effector cells are
mediators of that process [50, 51]. If this is so, in the context of
the current discussion, then either naturally occurring autoim-
mune T cells are more like T cell hybridomas in culture, and
have less stringent requirements for activation, or native epi-
thelium is more easily able to express co-stimulator molecules
than some of the examples now found in culture in various
laboratories.
I would also expect the appearance of anergy to be formally
regulated somehow. That is to say, for some immune interac-
tions anergy would not be appropriate and for others it might
be. One form of regulation might be the MHC-restnction that is
required of most complex T cell responses. It strikes me as
curious that many of the examples of anergy in vitro [33, 42, 43]
and with transgenic mice [35, 36] are restricted by MHC class II
Ea1J3 in mice or DRa/f3 in humans. Stimulation of T cells by
epithelium seems to prefer other restriction elements like Aa/J3
in mice or DQa//3 in humans [24, 27, 29, 30]. This notion is
somewhat bolstered by in vivo evidence in NOD mice with
diabetes. These mice do not express class II Ea/f3 genes; they
are thought to have an unique or abnormal form of Aa//3,
perhaps as a partial basis for their autoimmune pancreatitis [52].
When new Ea/13 genes are used to reconstitute NOD mice by
interbreeding or the transgenic route, their autoimmunity dis-
appears [53—55]. More recently, some normal haplotype Aa113
transgenes [53—55] have also been attenuating in the progeny of
NOD chimeras. Since the presence or absence of MHC genes
[56] and/or non-MHC genes, like superantigens [57], will affect
the emergence of certain T cell repertoires, perhaps suscepti-
bility to autoimmunity is polymorphic, and a reaction to self is
preferred in the absence of selected MHC (or other yet to be
described) restriction elements in disease-prone genotypes.
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